Biotechnology: Cutting remarks

UK Only Article:  standard article Issue:  The Saudi blueprint Fly Title:  Biotechnology Rubric:  A gene-editing company files for an IPO Main image:  20160109_WBD001_0.jpg AS DIFFICULT sales pitches go, this one is hard to beat. This biotech company has burned through $75m in the past few years and has not yet started clinical work on a drug candidate. It says it will be many years, “if ever”, before it has something ready to commercialise. If this were not enough, not only is there a thorny patent thicket to manage but the firm must fight and win a case seeking to overturn its own intellectual-property claims on the ground that it was not the first to invent them. Despite all this, shares in Editas Medicine, which filed on January 4th for an initial public offering, look set to draw great interest from investors. It will be an opportunity to buy into a revolutionary new technology called CRISPR-Cas9, which allows DNA to be cut and edited almost as easily as one might rewrite a document on a ...
Source: Biotechnology - Category: Biotechnology Source Type: news